Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

Summary

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aims of this prospective study is to investigate the efficacy of Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple therap.

Conditions

• Helicobacter Pylori Infection

Interventions

DRUG

Saccharomyces boulardii

500mg bid

DRUG

Esomeprazole

20mg bid

DRUG

Amoxicillin

1.0g bid

DRUG

Clarithromycin

0.5g bid

DRUG

Bismuth potassium citrate

0.22g bid

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Central Hospital of Xiaogan

  collaborator OTHER

• Xiaogan First People's Hospital

  collaborator UNKNOWN

• Hubei Aerospace Hospital

  collaborator UNKNOWN

• The Third People's Hospital of Hubei Province

  collaborator OTHER

• Wuhan University

  collaborator OTHER

• Anlu Puai Hospital

  collaborator UNKNOWN

• Huazhong University of Science and Technology

  lead OTHER

Principal Investigators

• Bin Cheng, Doctor · Tongji Hospital

• Yuchong Zhao, Doctor · Tongji Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

22 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-11-11

Primary Completion

2020-06-10

Completion

2020-12-31

Countries

• China

Study Locations